Acadian Asset Management
PTGX icon

Acadian Asset Management’s Protagonist Therapeutics PTGX Stock Holding History

Acadian Asset Management’s Portfolio PTGX Stock Details PTGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-3,026
Closed -$146K – 1800
2025
Q1 		$146K Sell
3,026
-2,863
-49% -$120K ﹤0.01% 1300
2024
Q4 		$226K Buy
5,889
+3,502
+147% +$153K ﹤0.01% 1243
2024
Q3 		$106K Buy
+2,387
New +$96.4K ﹤0.01% 1578
2023
Q1 		– Sell
-9,199
Closed -$100K – 1922
2022
Q4 		$100K Sell
9,199
-128,001
-93% -$1.08M ﹤0.01% 1431
2022
Q3 		$1.16M Buy
+137,200
New +$1.3M 0.01% 765
2021
Q1 		– Sell
-15,349
Closed -$309K – 2273
2020
Q4 		$309K Buy
+15,349
New +$330K ﹤0.01% 1396
2019
Q4 		– Sell
-156,961
Closed -$1.89M – 2023
2019
Q3 		$1.89M Buy
+156,961
New +$1.98M 0.01% 698
2019
Q2 		– Sell
-242,862
Closed -$3.05M – 1999
2019
Q1 		$3.05M Sell
242,862
-13,358
-5% -$118K 0.01% 570
2018
Q4 		$1.73M Buy
256,220
+6,516
+3% +$51.7K 0.01% 601
2018
Q3 		$2.57M Buy
249,704
+15,874
+7% +$137K 0.01% 515
2018
Q2 		$1.57M Buy
233,830
+175,849
+303% +$1.35M 0.01% 622
2018
Q1 		$498K Buy
57,981
+48,522
+513% +$914K ﹤0.01% 864
2017
Q4 		$197K Buy
+9,459
New +$168K ﹤0.01% 960

Other funds holding PTGX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $652M AUM 198.07% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Acadian Asset Management's PTGX Position: Q2 2025 in Review

Acadian Asset Management sold out of Protagonist Therapeutics (PTGX) in Q2 2025, closing a stake of 3,026 shares — an estimated $146K sold.

Acadian Asset Management first reported a position in PTGX in Q4 2017 and held it in 13 quarters. The position peaked at $3.05M in Q1 2019. 272 funds tracked by Wall St. Rank hold PTGX as of Q2 2025.

  • Acadian Asset Management reported no remaining Protagonist Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Acadian Asset Management sold 3,026 Protagonist Therapeutics shares in Q2 2025, an estimated $146K.
  • Acadian Asset Management first reported a position in Protagonist Therapeutics in Q4 2017 and held it in 13 quarters.
  • Acadian Asset Management's Protagonist Therapeutics position peaked at $3.05M in Q1 2019.
  • 272 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q2 2025.

Based on Acadian Asset Management's 13F filing for Q2 2025, filed 7 Aug 2025.